Dr. Yasser Al-Darshaby, Vice President and Medical Director of Pfizer in Africa and the Middle East, stated that the company, in cooperation with its partner, “Biontech”, completed the first phase of the study successfully, which allowed to reach the ideal dose for children between the ages of 5-11 years and 2-5 years, in addition to to 6 months and two years.Beginning of the second and third stages
He also added that the second and third phases of the study were started, in order to better evaluate the vaccine in terms of safety and tolerability for the age group ranging from 5 to 11 years.
As for the age group from 6 months to 5 years, the company hopes to start the second and third stages of study within a few weeks from now, according to Dershaby. “We are proud of this study being carried out globally, especially at a time when it is most needed by children and families who are eagerly awaiting this vaccine,” he added.And the companies Pfizer and Biontech had found last March that the Corona virus vaccine was 100% effective for children aged 12 to 15 years, in a clinical trial on more than two thousand adolescents.
It was discovered that the vaccine generates strong antibody responses.
Also, last month, the US Food and Drug Administration allowed the Pfizer vaccine to be given to children between 12 and 15 years old.
Last month, the European Medicines Regulatory Authority also approved the vaccine for the same age group, as some Arab countries have approved it and have already begun giving it to adolescents.
When asked about pregnant mothers, Dr. Dershaby said that the study on this group had already begun in February of this year.
He also explained that phase II and III clinical trials will enable the company to evaluate safety and immune response in healthy pregnant women aged 18 years or older, and at 24-34 weeks gestation.
He revealed that the company plans to enroll nearly 4,000 women in more than 130 locations around the world to participate in the study for a period of approximately 7 to 10 months.